SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Philippe Devillier, Jean-François Dreyfus, Pascal Demoly, Moisés A Calderón, A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis, BMC Medicine, 2014, 12, 1, 71

    CrossRef

  2. 2
    Fulvio Braido, Federica Arcadipane, Fiorenza Marugo, Mituki Hayashi, Ruby Pawankar, Allergic rhinitis, Current Opinion in Allergy and Clinical Immunology, 2014, 14, 2, 168

    CrossRef

  3. 3
    Fulvio Braido, Francesca Sclifò, Matteo Ferrando, Giorgio Walter Canonica, New Therapies for Allergic Rhinitis, Current Allergy and Asthma Reports, 2014, 14, 4

    CrossRef

  4. 4
    Erminia Ridolo, Marcello Montagni, Valerie Melli, Fulvio Braido, Cristoforo Incorvaia, Giorgio Walter Canonica, Pharmacotherapy of allergic rhinitis: current options and future perspectives, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 73

    CrossRef

  5. 5
    Pascal Demoly, Anca Chiriac, Benoît Berge, Michel Rostin, Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response, Allergy, Asthma & Clinical Immunology, 2014, 10, 1, 29

    CrossRef

  6. 6
    Garry M. Walsh, A worldwide yearly survey of new data in adverse drug reactions and interactions, 2014,

    CrossRef

  7. 7
    Ignacio Jáuregui, Marta Ferrer, Joan Bartra, Alfonso del Cuvillo, Ignacio Dávila, Javier Montoro, Joaquim Mullol, Joaquín Sastre, Antonio Valero, Bilastine for the treatment of urticaria, Expert Opinion on Pharmacotherapy, 2013, 14, 11, 1537

    CrossRef

  8. 8
    Ole D. Wolthers, Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria, BioMed Research International, 2013, 2013, 1

    CrossRef

  9. 9
    Deborah Gentile, Ashton Bartholow, Erkka Valovirta, Glenis Scadding, David Skoner, Current and Future Directions in Pediatric Allergic Rhinitis, The Journal of Allergy and Clinical Immunology: In Practice, 2013, 1, 3, 214

    CrossRef

  10. 10
    Michael Nye, Shara Rudner, Leonard Bielory, Emerging therapies in allergic conjunctivitis and dry eye syndrome, Expert Opinion on Pharmacotherapy, 2013, 14, 11, 1449

    CrossRef

  11. 11
    Kenneth C. Lasseter, Ander Sologuren, Anna La Noce, Stacy C. Dilzer, Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency, Clinical Drug Investigation, 2013, 33, 9, 665

    CrossRef

  12. 12
    L. Klimek, A. Sperl, Evidenzbasierte Therapieoptionen von Allergien im HNO-Bereich, HNO, 2013, 61, 6, 525

    CrossRef

  13. 13
    B. Sádaba, A. Gómez-Guiu, J. R. Azanza, I. Ortega, R. Valiente, Oral Availability of Bilastine, Clinical Drug Investigation, 2013, 33, 5, 375

    CrossRef

  14. You have free access to this content14
    G. Roberts, M. Xatzipsalti, L. M. Borrego, A. Custovic, S. Halken, P. W. Hellings, N. G. Papadopoulos, G. Rotiroti, G. Scadding, F. Timmermans, E. Valovirta, Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology, Allergy, 2013, 68, 9
  15. 15
    Vanesa González-Núñez, Antonio Valero, Joaquim Mullol, Safety evaluation of desloratadine in allergic rhinitis, Expert Opinion on Drug Safety, 2013, 12, 3, 445

    CrossRef

  16. 16
    Hong X. Ding, Kevin K.-C. Liu, Subas M. Sakya, Andrew C. Flick, Christopher J. O’Donnell, Synthetic approaches to the 2011 new drugs, Bioorganic & Medicinal Chemistry, 2013, 21, 11, 2795

    CrossRef

  17. 17
    Ignacio Jáuregui, Eduardo García-Lirio, Ana Ma Soriano, Pedro M Gamboa, Ignacio Antépara, An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria, Expert Review of Clinical Immunology, 2012, 8, 1, 33

    CrossRef

  18. 18
    Natalie J. Carter, Bilastine, Drugs, 2012, 72, 9, 1257

    CrossRef

  19. 19
    Katherine A. Lyseng-Williamson, Natalie J. Carter, Bilastine: a guide to its use in the treatment of symptomatic allergic rhinoconjunctivitis and urticaria, Drugs & Therapy Perspectives, 2012, 28, 11, 1

    CrossRef

  20. 20
    Katherine A. Lyseng-Williamson, Natalie A. Carter, Bilastine: a guide to its use in the treatment of symptomatic allergic rhinoconjunctivitis and urticaria, Drugs & Therapy Perspectives, 2012, 28, 11, 1

    CrossRef

  21. 21
    Claus Graff, Johannes J. Struijk, Jørgen K. Kanters, Mads P. Andersen, Egon Toft, Benoît Tyl, Effects of Bilastine on T-wave Morphology and the QTc Interval, Clinical Drug Investigation, 2012, 32, 5, 339

    CrossRef

  22. 22
    Joaquín Sastre, Joaquim Mullol, Antonio Valero, Román Valiente, Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis, Current Medical Research and Opinion, 2012, 28, 1, 121

    CrossRef

  23. 23
    Jean Bousquet, Ignacio Ansótegui, G. Walter Canonica, Torsten Zuberbier, Carlos E. Baena-Cagnani, Claus Bachert, Alvaro A. Cruz, Sandra N. González, Piotr Kuna, Mario Morais-Almeida, Joaquim Mullol, Dermot P. Ryan, Mario Sánchez-Borges, Román Valiente, Martin K. Church, Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review, Current Medical Research and Opinion, 2012, 28, 1, 131

    CrossRef

  24. 24
    Ivan Pavić, Iva Hojsak, Jasna Čepin-Bogović, Evidence-Based Management of Chronic Urticaria in Children, Pediatric Allergy, Immunology, and Pulmonology, 2012, 25, 4, 198

    CrossRef

  25. 25
    Benoît Tyl, Meriam Kabbaj, Sara Azzam, Ander Sologuren, Román Valiente, Elizabeth Reinbolt, Kathryn Roupe, Nathalie Blanco, William Wheeler, Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT-Concentration Analysis, The Journal of Clinical Pharmacology, 2012, 52, 6
  26. 26
    Steven J. Collier, Xiang Wu, Zhiying Poh, Gurubatham Abraham Rajkumar, Larry Yet, Alternative Synthesis of Bilastine, Synthetic Communications, 2011, 41, 9, 1394

    CrossRef

  27. 27
    Martin K. Church, Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans, Inflammation Research, 2011, 60, 12, 1107

    CrossRef

  28. 28
    Martin K Church, Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria, Expert Opinion on Drug Safety, 2011, 10, 5, 779

    CrossRef

  29. 29
    Torsten Zuberbier, Jean Bousquet, Giorgio Walter Canonica, Anca-Mirela Chiriac, Une nouvelle impulsion dans le traitement des allergies, Revue Française d'Allergologie, 2011, 51, 8, H8

    CrossRef

  30. 30
    Leonard Bielory, Allergic Conjunctivitis and the Impact of Allergic Rhinitis, Current Allergy and Asthma Reports, 2010, 10, 2, 122

    CrossRef

  31. You have free access to this content31
    C. Bachert, P. Kuna, T. Zuberbier, Bilastine in allergic rhinoconjunctivitis and urticaria, Allergy, 2010, 65,
  32. 32
    T. Zuberbier, A. Oanta, E. Bogacka, I. Medina, F. Wesel, P. Uhl, I. Antépara, I. Jáuregui, R. Valiente, Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study, Allergy, 2010, 65, 4
  33. 33
    I. S. Gushchin, Inverse agonists of H1-receptors as promising antiallergy agents (a review), Pharmaceutical Chemistry Journal, 2010, 44, 1, 1

    CrossRef

  34. 34
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2009, 18, 6
  35. 35
    Jerzy Kruszewski, Leki przeciwhistaminowe w leczeniu alergicznego nieżytu nosa – uaktualnienie 2008/2009, Otolaryngologia Polska, 2009, 63, 7, 5

    CrossRef